Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca and The Medicines Company have signed a global development and commercialization agreement for acute ischaemic heart disease compounds.
Subscribe to our email newsletter
The collaboration begins with a US co-promotion for AstraZeneca’s oral antiplatelet medicine BRILINTA, under which The Medicines Company sales force will begin supporting the product in May 2012.
The Medicines Company senior vice president and chief customer officer Brent Furse said, "Our goal in joining this global collaboration with AstraZeneca is to help improve patient care with a comprehensive suite of solutions for acute ischaemic heart disease."
As a part of the global collaboration, a joint development committee and a joint commercialization committee were established to prepare and deliver commercialization plans related to AstraZeneca’s BRILINTA and The Medicines Company’s Angiomax (bivalirudin) for injection and cangrelor.
Under the four-year US BRILINTA co-promotion agreement, The Medicines Company will receive $15m per year from AstraZeneca for performing pre-agreed commercialization.
The Medicines Company is also entitled to receive an additional $5m per year if performance thresholds are met.